Rituximab in the treatment of factor XIII inhibitor possibly caused by Ciprofloxacin.
Miesbach
Wolfgang
W
Johann Wolfgang Goethe University, Frankfurt/Main, Department of Internal Medicine III, Germany. miesbach@em.uni-frankfurt.de
D000890:Anti-Infective Agents / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000096:biosynthesis*; D001779:Blood Coagulation Factors / Q000378:metabolism; D002939:Ciprofloxacin / Q000009:adverse effects* / Q000494:pharmacology*; D015942:Factor VIIa / Q000627:therapeutic use; D005176:Factor XIII / Q000037:antagonists & inhibitors* / Q000096:biosynthesis* / Q000627:therapeutic use; D005177:Factor XIII Deficiency / Q000235:genetics; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D000069283:Rituximab; D013927:Thrombosis / Q000188:drug therapy; D013997:Time Factors; D014859:Warfarin / Q000494:pharmacology
D000890:Anti-Infective Agents; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D001779:Blood Coagulation Factors; D007155:Immunologic Factors; D011994:Recombinant Proteins; D000069283:Rituximab; D002939:Ciprofloxacin; D014859:Warfarin; D005176:Factor XIII; D015942:Factor VIIa